Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief
By Kunal Das Oct 12 (Reuters) - Bausch + Lomb said on Monday that CEO Brent Saunders will leave the eye-care company by ...
Model output · Signal date 2026-10-13
Bausch & Lomb Corp (BLCO) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Middle 30%
of 5379 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$5.65B
mid-cap · #3 of 8 peers
Summary
Bausch & Lomb Corp (BLCO) stock forecast summary
On Oct. 13, 2026, BLCO is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Bausch & Lomb Corp is a mid-cap company with a market capitalization of $5.65B. It ranks number 3 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for BLCO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BLCO included.
Follow BLCO freePrice
BLCO price chart and AI forecast
Cross-section · 2026-10-13
How BLCO ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Bausch & Lomb Corp (BLCO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.
Valuation & Market
| Metric | BLCO | Rank |
|---|---|---|
| Market Cap | $5.65B | 3/8 |
| P/B Ratio | 0.89x | 6/7 |
| EPS | $-0.88 | – |
| Book Value/Share | $17.85 | – |
| Revenue/Share | $14.91 | – |
| FCF/Share | $0.38 | – |
Profitability & Margins
| Metric | BLCO | Rank |
|---|---|---|
| ROE | -2.7% | – |
| ROA | -1.2% | – |
| ROIC | 2.7% | 4/6 |
| Operating Margin | 6.1% | 2/6 |
| Net Margin | -3.2% | – |
| EBT Margin | -1.2% | 5/6 |
| Tax Rate | -150.8% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | BLCO | Rank |
|---|---|---|
| Current Ratio | 1.55x | 5/7 |
| Quick Ratio | 1.02x | 5/7 |
| D/E Ratio | 1.16x | 2/7 |
| Financial Leverage | 2.17x | 2/7 |
| Interest Coverage | 0.9x | 5/6 |
| Working Capital | $1.03B | 1/7 |
Cash Flow
| Metric | BLCO | Rank |
|---|---|---|
| Operating Cash Flow | $458M | 3/8 |
| Free Cash Flow | $137M | 2/6 |
| Capital Spending | -$321M | 5/6 |
| OCF Growth YoY | 146.2% | – |
| FCF/Sales | 2.6% | 2/6 |
| CapEx/Sales | 6.0% | 3/6 |
Operational Efficiency
| Metric | BLCO | Rank |
|---|---|---|
| Asset Turnover | 0.38x | 5/7 |
| Receivables Turnover | 4.6x | 6/7 |
| Fixed Assets Turnover | 3.0x | 6/7 |
| Days Sales Outstanding | 80 days | 2/7 |
Income Statement
| Metric | BLCO | Rank |
|---|---|---|
| Total Revenue | $5.32B | 1/7 |
| Operating Income | $323M | 3/7 |
| Net Income | -$171M | – |
| R&D Expense | $404M | 2/6 |
| SG&A Expense | $2.22B | 1/7 |
Dividend & Shareholder Information
| Metric | BLCO | Rank |
|---|---|---|
| Shares Outstanding | 357M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2.92B | 21.1% of assets |
| Cash & Short-term Investments | $367M | 2.6% of assets |
| Accounts Receivable | $1.16B | 8.4% of assets |
| Inventory | $999M | 7.2% of assets |
| Total Liabilities | $7.42B | 53.5% of assets |
| Short-term Debt | $1.46B | 10.6% of assets |
Quarterly Financial Reports
BLCO quarterly financials and insider trading
Industry Peers · Ophthalmic Goods
Bausch & Lomb Corp (BLCO) industry peers
Companies classified under the same SEC industry code as Bausch & Lomb Corp (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BLCO Bausch & Lomb Corp | ▶ | $5.65B |
| ALC Alcon Inc | ▼ | $30.71B |
| COO Cooper Companies, Inc. | ▼ | $10.38B |
| WRBY Warby Parker Inc. | ▲ | $3.21B |
| EYE National Vision Holdings, Inc. | ▼ | $1.35B |
| STAA Staar Surgical Co | ▶ | $1.08B |
| RXST Rxsight, Inc. | ▲ | $188M |
| LUCY Innovative Eyewear Inc | ▲ | $8M |
Where BLCO sits on the market map
Industrial Applications and Services · Ophthalmic Goods
News
Bausch & Lomb Corp (BLCO) stock news
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Oct 12 (Reuters) - Bausch + Lomb said on Monday that CEO Brent Saunders will depart the company after a mutual agreement with ...
Bausch + Lomb Appoints Thomas Appio as Interim CEO
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s ...
FAQ
Bausch & Lomb Corp (BLCO) stock forecast FAQ
What is the Bausch & Lomb Corp (BLCO) stock forecast?
On Oct. 13, 2026, BLCO is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Bausch & Lomb Corp stock predictions?
A per-ticker accuracy statistic for BLCO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bausch & Lomb Corp forecasts updated?
Bausch & Lomb Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Bausch & Lomb Corp's industry peers?
8 issuers in our coverage, BLCO included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Warby Parker Inc. (WRBY), National Vision Holdings, Inc. (EYE), Staar Surgical Co (STAA), Rxsight, Inc. (RXST).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.